文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

MRI引导的超局灶高剂量率近距离放疗治疗局限性前列腺癌:可行性研究中位4年结果

MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-03-27

这项可行性研究纳入30例NCCN低危(13%)至中危(87%)局限性前列腺癌患者,2013年5月至2016年4月接受MRI引导超局灶高剂量率近距离放疗,单次19 Gy、5 mm边界。中位随访4年,无>2级泌尿或>1级胃肠毒性,但50%患者勃起功能恶化,4年生化无病生存率70%(95%CI 52%-93%),作者认为肿瘤控制不佳可能源于患者选择不当。

要点

  • 30例低至中危前列腺癌接受单次19 Gy超局灶高剂量率近距离放疗,中位随访4年。
  • 无>2级泌尿或>1级胃肠毒性,但50%患者勃起功能恶化至中/重度。
  • 4年生化无病生存率70%(95%CI 52%-93%),9例前列腺内复发中7例为野外复发。

核心结论

  • 超局灶高剂量率近距离放疗泌尿或胃肠毒性极小,对生活质量影响有限,但勃起功能早期下降。
  • 肿瘤控制结果不佳,4年生化无病生存率为70%(95%CI 52%-93%),最可能原因是患者选择不佳。

研究设计与样本

  • 可行性研究,纳入30例NCCN低危(13%)至中危(87%)局限性前列腺癌患者,2013年5月至2016年4月治疗。
  • 经融合经直肠超声/MRI引导植入,随后1.5 T MRI调整轮廓和验证导管位置,单次19 Gy、5 mm边界。
  • 中位随访4年,中位年龄71岁(四分位距68-73),中位初始前列腺特异性抗原7.3 ng/mL(5.2-8.1)。

主要发现

  • 无>2级泌尿毒性或>1级胃肠毒性发生;国际前列腺症状评分仅暂时恶化。
  • 50%患者治疗前轻度勃起功能障碍恶化至中/重度;性活动和疲倦方面见长期临床相关生活质量下降,情绪和认知功能改善。
  • 4年生化无病生存率70%(95%CI 52%-93%),无转移生存率93%(85%-100%),总生存率100%。
  • 9例前列腺内复发中7例为野外复发。

关键数值与推荐

  • 生化复发定义为前列腺特异性抗原最低值+2 ng/mL(Phoenix标准)。
  • 毒性分级采用不良事件通用术语标准4.0版;生活质量采用RAND-36、欧洲癌症研究与治疗组织QLQ-C30和PR25量表。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出肿瘤控制结果不佳,最可能原因是患者选择不佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For the treatment of localized prostate cancer, focal therapy has the potential to cure with fewer side effects than traditional whole-gland treatments. We report an update on toxicity, quality of life (QoL), and tumor control in our magnetic resonance imaging (MRI)-guided ultrafocal high-dose-rate brachytherapy cohort. METHODS AND MATERIALS: Disease status was evaluated by systematic biopsies and 3T multiparametric MRI. The brachytherapy implant procedure under fused transrectal ultrasound/MRI guidance was followed by a 1.5 T MRI for contour adjustments and catheter position verification. A single dose of 19 Gy was delivered to the tumor with a margin of 5 mm. Genitourinary (GU) toxicity, gastrointestinal (GI) toxicity, and erectile dysfunction (ED) were graded with the Common Terminology Criteria for Adverse Events version 4.0. QoL was measured with RAND-36, European Organisation for Research and Treatment of Cancer QLQ-C30 and PR25. International Prostate Symptom Scores and International Index of Erectile Function scores were obtained. Prostate-specific antigen level was monitored, with biochemical recurrence defined as nadir + 2 ng/mL (Phoenix). RESULTS: Thirty patients with National Comprehensive Cancer Network low- (13%) to intermediate-risk (87%) prostate cancer were treated between May 2013 and April 2016. Median follow-up was 4 years. Median age was 71 years (interquartile range, 68-73) and median initial prostate-specific antigen level was 7.3 ng/mL (5.2-8.1). Maximum Gleason score was 4 + 3 = 7 (in 2 patients). All tumors were radiologic (MRI) stage T2. No grade >2 GU or >1 GI toxicity occurred. International Prostate Symptom Scores only deteriorated temporarily. Mild pretreatment ED deteriorated to moderate/severe ED in 50% of patients. Long-term clinically relevant QoL deterioration was seen in sexual activity and tiredness, whereas emotional and cognitive functioning improved. At 4 years, biochemical disease-free survival was 70% (95% confidence interval, 52%-93%), metastases-free survival was 93% (85%-100%), and overall survival was 100%. Of intraprostatic recurrences, 7 of 9 were out of field. CONCLUSIONS: Ultrafocal high-dose-rate brachytherapy conveys minimal GU or GI toxicity and has a marginal effect on QoL. An early decline in erectile function was seen. Tumor control outcomes are poor (biochemical disease-free survival of 70% [52%-93%] at 4 years), most likely as a result of poor patient selection.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Peters M, van Son MJ, Moerland MA, et al. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. Int J Radiat Oncol Biol Phys. 2019. PMID: 30926575. doi:10.1016/j.ijrobp.2019.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。